Case report: Marathon runner with severe autonomic failure. Garland EM, Raj SR, Demartinis N, Robertson D (2005) Lancet 366 Suppl 1: S13 Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Ahmed MR, Berthet A, Bychkov E, Porras G, Li Q, Bioulac BH, Carl YT, Bloch B, Kook S, Aubert I, Dovero S, Doudnikoff E, Gurevich VV, Gurevich EV, Bezard E (2010) Sci Transl Med 2: 28ra28 Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Ohlin KE, Francardo V, Lindgren HS, Sillivan SE, O'Sullivan SS, Luksik AS, Vassoler FM, Lees AJ, Konradi C, Cenci MA (2011) Brain 134: 2339-57 Mitochondrial abnormalities in the putamen in Parkinson's disease dyskinesia. Naydenov AV, Vassoler F, Luksik AS, Kaczmarska J, Konradi C (2010) Acta Neuropathol 120: 623-31 The thorny problem of dyskinesias: dendritic spines, synaptic plasticity, and striatal dysfunction. Deutch AY (2014) Biol Psychiatry 75: 676-7 cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. Andersson M, Konradi C, Cenci MA (2001) J Neurosci 21: 9930-43 Ventral striatal network connectivity reflects reward learning and behavior in patients with Parkinson's disease. Petersen K, Van Wouwe N, Stark A, Lin YC, Kang H, Trujillo-Diaz P, Kessler R, Zald D, Donahue MJ, Claassen DO (2018) Hum Brain Mapp 39: 509-521 L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Bezard E, Gross CE, Qin L, Gurevich VV, Benovic JL, Gurevich EV (2005) Neurobiol Dis 18: 323-35 Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model. Jones CK, Engers DW, Thompson AD, Field JR, Blobaum AL, Lindsley SR, Zhou Y, Gogliotti RD, Jadhav S, Zamorano R, Bogenpohl J, Smith Y, Morrison R, Daniels JS, Weaver CD, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR (2011) J Med Chem 54: 7639-47 Molecular profiling of experimental Parkinson's disease: direct analysis of peptides and proteins on brain tissue sections by MALDI mass spectrometry. Pierson J, Norris JL, Aerni HR, Svenningsson P, Caprioli RM, Andrén PE (2004) J Proteome Res 3: 289-95 Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys. Chen Q, Andersen AH, Zhang Z, Ovadia A, Cass WA, Gash DM, Avison MJ (1999) Exp Neurol 158: 63-75 Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, Rodriguez AL, Marlo JE, de Paulis T, Thompson AD, Days EL, Nalywajko T, Austin CA, Williams MB, Ayala JE, Williams R, Lindsley CW, Conn PJ (2008) Mol Pharmacol 74: 1345-58 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease. Ferguson MC, Nayyar T, Deutch AY, Ansah TA (2010) Neuropharmacology 59: 31-6 Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Iderberg H, Maslava N, Thompson AD, Bubser M, Niswender CM, Hopkins CR, Lindsley CW, Conn PJ, Jones CK, Cenci MA (2015) Neuropharmacology 95: 121-9 Glutamate receptors as therapeutic targets for Parkinson's disease. Johnson KA, Conn PJ, Niswender CM (2009) CNS Neurol Disord Drug Targets 8: 475-91 Focused stimulation of dorsal subthalamic nucleus improves reactive inhibitory control of action impulses. van Wouwe NC, Pallavaram S, Phibbs FT, Martinez-Ramirez D, Neimat JS, Dawant BM, D'Haese PF, Kanoff KE, van den Wildenberg WPM, Okun MS, Wylie SA (2017) Neuropsychologia 99: 37-47 Validating an objective video-based dyskinesia severity score in Parkinson's disease patients. Rao AS, Dawant BM, Bodenheimer RE, Li R, Fang J, Phibbs F, Hedera P, Davis T (2013) Parkinsonism Relat Disord 19: 232-7 Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, Mach U, Stark H, Leriche L, Håkansson K, Bioulac BH, Gross CE, Sokoloff P, Fisone G, Gurevich EV, Bloch B, Bezard E (2005) Parkinsonism Relat Disord 11 Suppl 1: S25-9 Glutamate receptors and Parkinson's disease: opportunities for intervention. Marino MJ, Valenti O, Conn PJ (2003) Drugs Aging 20: 377-97 Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK (2013) J Parkinsons Dis 3: 231-9
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.